Binding of SARS-CoV-2 protein ORF9b to mitochondrial translocase TOM70 prevents its interaction with chaperone HSP90

被引:9
|
作者
Ayinde, Kehinde S. [1 ,2 ]
Pinheiro, Glaucia M. S. [1 ]
Ramos, Carlos H. I. [1 ]
机构
[1] Univ Campinas UNICAMP, Inst Chem, BR-13083970 Campinas, SP, Brazil
[2] Univ Campinas UNICAMP, Inst Biol, Campinas, SP, Brazil
基金
巴西圣保罗研究基金会;
关键词
HSP90; TOM70; SARS-CoV-2; COVID-19; Protein-protein interaction; Immune evasion; TRYPTOPHAN;
D O I
10.1016/j.biochi.2022.05.016
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The emergence of the COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), remains a great threat to global health. ORF9b, an important accessory protein of SARS-CoV-2, plays a critical role in the viral host interaction, targeting TOM70, a member of the mitochondrial translocase of the outer membrane complex. The assembly between ORF9b and TOM70 is implicated in disrupting mitochondrial antiviral signaling, leading to immune evasion. We describe the expression, purification, and characterization of ORF9b alone or coexpressed with the cytosolic domain of human TOM70 in E. coli. ORF9b has 97 residues and was purified as a homodimer with an molecular mass of 22 kDa as determined by SEC-MALS. Circular dichroism experiments showed that Orf9b alone exhibits a random conformation. The ORF9b-TOM70 complex characterized by CD and differential scanning calorimetry showed that the complex is folded and more thermally stable than free TOM70, indicating strong binding. Importantly, proteineprotein interaction assays demonstrated that full-length human Hsp90 is capable of binding to free TOM70 but not to the ORF9b-TOM70 complex. To narrow down the nature of this inhibition, the isolated C-terminal domain of Hsp90 was also tested. These results were used to build a model of the mechanism of inhibition, in which ORF9b efficiently targets two sites of interaction between TOM70 and Hsp90. The findings showed that ORF9b complexed with TOM70 prevents the interaction with Hsp90, and this is one major explanation for SARS-CoV-2 evasion of host innate immunity via the inhibition of the interferon activation pathway. (c) 2022 Elsevier B.V. and Societe Francaise de Biochimie et Biologie Moleculaire (SFBBM). All rights reserved.
引用
收藏
页码:99 / 106
页数:8
相关论文
共 43 条
  • [31] Piperaquine- and Aspirin-Mediated Protective Role of HSP70 and HSP90 as Modes to Strengthen the Natural Immunity against Potent SARS-CoV-2
    Aireshidi, Fayez Saud
    Ginawi, Ibrahim Abdelmageed
    Hussain, Malik Asif
    Arif, Jamal Mohammad
    BIOINTERFACE RESEARCH IN APPLIED CHEMISTRY, 2021, 11 (04): : 12364 - 12379
  • [32] The TPR2B Domain of the Hsp70/Hsp90 Organizing Protein (Hop) May Contribute Towards Its Dimerization
    Longshaw, Victoria M.
    Stephens, Linda L.
    Daniel, Sheril
    Blatch, Gregory L.
    PROTEIN AND PEPTIDE LETTERS, 2009, 16 (04): : 402 - 407
  • [33] Computational investigation of the inhibitory interaction of IRF3 and SARS-CoV-2 accessory protein ORF3b
    Bai, Ganggang
    Zeng, Xincheng
    Zhang, Linghao
    Wang, Yanjing
    Ma, Buyong
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2024, 712
  • [34] HSP90 Inhibitors Modulate SARS-CoV-2 Spike Protein Subunit 1-Induced Human Pulmonary Microvascular Endothelial Activation and Barrier Dysfunction
    Biancatelli, Ruben Manuel Luciano Colunga
    Solopov, Pavel A.
    Gregory, Betsy
    Khodour, Yara
    Catravas, John D.
    FRONTIERS IN PHYSIOLOGY, 2022, 13
  • [35] The Interaction between SARS-CoV-2 Nucleocapsid Protein and UBC9 Inhibits MAVS Ubiquitination by Enhancing Its SUMOylation
    Huang, Congcong
    Yin, Yiping
    Pan, Pan
    Huang, Yanping
    Chen, Siwei
    Chen, Junkai
    Wang, Ju
    Xu, Guoqing
    Tao, Xuan
    Xiao, Xiao
    Li, Jian
    Yang, Jing
    Jin, Zhixiong
    Li, Bei
    Tong, Zhaohui
    Du, Weixing
    Liu, Long
    Liu, Zhixin
    VIRUSES-BASEL, 2023, 15 (12):
  • [36] Mulberrofuran G, a Mulberry Component, Prevents SARS-CoV-2 Infection by Blocking the Interaction between SARS-CoV-2 Spike Protein S1 Receptor-Binding Domain and Human Angiotensin-Converting Enzyme 2 Receptor
    Kim, Young Soo
    Kim, Buyun
    Kwon, Eun-Bin
    Chung, Hwan-Suck
    Choi, Jang-Gi
    NUTRIENTS, 2022, 14 (19)
  • [37] Fast Prediction of Binding Affinities of SARS-CoV-2 Spike Protein and Its Mutants with Antibodies through Intermolecular Interaction Modeling-Based Machine Learning
    Williams, Alexander H.
    Zhan, Chang-Guo
    JOURNAL OF PHYSICAL CHEMISTRY B, 2022, 126 (28): : 5194 - 5206
  • [38] SARS-CoV-2 ORF9b antagonizes type I and III interferons by targeting multiple components of the RIG-I/MDA-5-MAVS, TLR3-TRIF, and cGAS-STING signaling pathways
    Han, Lulu
    Zhuang, Meng-Wei
    Deng, Jian
    Zheng, Yi
    Zhang, Jing
    Nan, Mei-Ling
    Zhang, Xue-Jing
    Gao, Chengjiang
    Wang, Pei-Hui
    JOURNAL OF MEDICAL VIROLOGY, 2021, 93 (09) : 5376 - 5389
  • [39] Molecular Dynamics Simulation Study of the Interaction between Human Angiotensin Converting Enzyme 2 and Spike Protein Receptor Binding Domain of the SARS-CoV-2 B.1.617 Variant
    Antony, Priya
    Vijayan, Ranjit
    BIOMOLECULES, 2021, 11 (08)
  • [40] Interaction sites in the receptor-binding domain (RBD) of the spike wild-type SARS-CoV-2 protein of the posaconazole (POS) drug and its quantum–mechanical characterization
    Juan Carlos Santiago-Jiménez
    Fray De Landa Castillo-Alvarado
    Alberto García-Quiroz
    Gabriel Ramírez-Damaso
    MRS Advances, 2023, 8 : 1279 - 1283